Brokerages Set Indivior PLC (NASDAQ:INDV) Price Target at $40.29

Shares of Indivior PLC (NASDAQ:INDV) have earned a consensus recommendation of “Moderate Buy” from the eight ratings firms that are currently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $40.2857.

A number of brokerages recently issued reports on INDV. Weiss Ratings lowered Indivior from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday. Barclays started coverage on Indivior in a report on Thursday, June 18th. They set an “overweight” rating and a $46.00 price objective on the stock. Finally, Zacks Research lowered Indivior from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 29th.

Insider Buying and Selling at Indivior

In related news, CFO Ryan Preblick sold 36,000 shares of the company’s stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $37.70, for a total value of $1,357,200.00. Following the completion of the sale, the chief financial officer directly owned 284,751 shares of the company’s stock, valued at $10,735,112.70. This represents a 11.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Christian Heidbreder sold 18,586 shares of the stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $41.14, for a total transaction of $764,628.04. Following the transaction, the insider owned 209,337 shares in the company, valued at approximately $8,612,124.18. The trade was a 8.15% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.74% of the company’s stock.

Institutional Investors Weigh In On Indivior

Large investors have recently modified their holdings of the business. Quarry LP bought a new position in shares of Indivior during the third quarter valued at approximately $26,000. Raymond James Financial Inc. purchased a new stake in Indivior during the second quarter worth $26,000. Salomon & Ludwin LLC purchased a new stake in Indivior during the fourth quarter worth $30,000. Harbor Capital Advisors Inc. boosted its position in Indivior by 309.9% during the 4th quarter. Harbor Capital Advisors Inc. now owns 1,033 shares of the company’s stock valued at $37,000 after acquiring an additional 781 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd boosted its position in Indivior by 72.7% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,093 shares of the company’s stock valued at $39,000 after acquiring an additional 460 shares in the last quarter. Institutional investors own 60.33% of the company’s stock.

Indivior Price Performance

Shares of INDV opened at $40.21 on Tuesday. The firm has a market capitalization of $4.90 billion, a price-to-earnings ratio of 20.62 and a beta of 0.86. Indivior has a 1-year low of $15.00 and a 1-year high of $42.81. The company has a 50-day moving average of $38.59 and a 200 day moving average of $35.04.

Indivior (NASDAQ:INDV) last issued its earnings results on Tuesday, March 31st. The company reported $0.96 EPS for the quarter. The business had revenue of $317.00 million for the quarter. Indivior had a net margin of 19.44% and a negative return on equity of 219.26%. On average, equities analysts anticipate that Indivior will post 4.05 earnings per share for the current fiscal year.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.